Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XEXPT
ADC Name
SGN-STNV
Synonyms
SGNSTNV; SGN STNV
   Click to Show/Hide
Organization
Seagen Inc.
Drug Status
Phase 1
Indication
In total 12 Indication(s)
Adenocarcinoma [ICD11:2D40]
Phase 1
Appendiceal adenocarcinoma [ICD11:2B81]
Phase 1
Breast cancer [ICD11:2C60-2C65]
Phase 1
Colorectal cancer [ICD11:2B91]
Phase 1
Endometrial cancer [ICD11:2C76]
Phase 1
Esophageal cancer [ICD11:2B70]
Phase 1
Gastric cancer [ICD11:2B72]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Ovarian cancer [ICD11:2C73]
Phase 1
Pancreatic cancer [ICD11:2C10]
Phase 1
Pseudomyxoma peritonei [ICD11:2D91]
Phase 1
Uterine cancer [ICD11:2C78]
Phase 1
Antibody Name
Undisclosed
Antigen Name
Onco-foetal sialyl-Tn
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04665921
Phase 1
A phase 1 study of SGN-STNV in advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04665921  Clinical Status Phase 1
Clinical Description A phase 1 study of SGN-STNV in advanced solid tumors.
References
Ref 1 A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.